Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-24-040187
Filing Date
2024-09-12
Accepted
2024-09-12 06:07:46
Documents
92
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 6-K inpha-20240630.htm   iXBRL 6-K 218735
2 EX-99.2 inpha-20240630_d2.htm   iXBRL EX-99.2 1139066
  Complete submission text file 0001628280-24-040187.txt   8168002

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inpha-20240630.xsd EX-101.SCH 100249
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT inpha-20240630_cal.xml EX-101.CAL 101879
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT inpha-20240630_def.xml EX-101.DEF 326790
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inpha-20240630_lab.xml EX-101.LAB 719417
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inpha-20240630_pre.xml EX-101.PRE 515842
94 EXTRACTED XBRL INSTANCE DOCUMENT inpha-20240630_htm.xml XML 1543125
Mailing Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE I0 13009
Business Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE I0 13009 33430303030
Innate Pharma SA (Filer) CIK: 0001598599 (see all company filings)

EIN.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39084 | Film No.: 241293821
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)